We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Robotic Surgery Complications Extensively Underreported

By HospiMedica International staff writers
Posted on 12 Sep 2013
A new study suggests that device-related robotic surgery complications reported to the US Food and Drug Administration (FDA) are grossly underreported.

Researchers at Johns Hopkins University (JHU; Baltimore, MD, USA) searched the FDA device-related complications database, LexisNexis, news media reports, and the public access to court electronic records (PACER) to identify robotic surgery-related complications over a 12-year period (January 1, 2000 to August 1, 2012). More...
Cases from LexisNexis and PACER were cross-referenced with the FDA database to determine cases where FDA reports were inaccurate, filed late, or not filed.

The results showed that although more than one million robotic surgeries have been performed in the US since 2000, hospitals only reported 245 complications to the FDA during the study period, including 71 deaths and 174 nonfatal injuries; median time to report an event was 30 days. Eight cases were identified from the LexisNexis and PACER searches where FDA reports were improperly filed. In five of these, no report was filed within a mean follow-up of 4.1 years. In the three cases where a report was filed, the mean time between the event and the FDA report was almost two years.

While complications such as excessive bleeding were reported, there were other problems that may not have been reported correctly, or at all, the researchers speculated. For example, surgeons can accidentally cut the aorta during robotic surgery because they cannot feel how firm it is, but the data was unclear as to whether this would be reported as a surgeon- or device-related problem. They also cited a previous study in which nearly 57% of surgeons surveyed anonymously said that they had to convert to laparoscopic or open surgery after the robotic device malfunctioned; it is unclear how, or if, those errors are reported with the FDA. The study was published in the August 27, 2013, issue of the Journal for Healthcare Quality.

“The number reported is very low for any complex technology used over a million times. Decisions should not be made based on the information in the FDA database,” said study author associate professor of surgery Martin Makary, MD, of the JHU School of Medicine. “A broader roster of errors must be tracked as device-related problems. We need to be able to give patients answers to their questions about safety and how much risk is associated with the robot.”

Related Links:
Johns Hopkins University




Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
Ureteral Dilatation Balloon
Dornier Equinox
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.